AKBA - Akebia Therapeutics Stock Trading

Last year I created a public screen on Portfolio123, a web-based subscription service that allows you to backtest screens and ranking systems. It invests in companies in the Russell 3000 that spend heavily on R&D. There were four rules in the screen, but the most important were these: ...

Gainers:  XLNX +7.6% . MU +5.8% . SPG +5.8% . SMHI +5.3% . NLS +4.5% . More news on: Xilinx, Inc., Micron Technology, Inc., Simon Property Group, Inc., Stocks on the move, , Read more ...

Japan's Ministry of Health, Labor and Welfare has approved Akebia Therapeutics' (NASDAQ: AKBA ) vadadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for treatment of adults with anemia due to chronic kidney disease (CKD) in both dialysis-dependent and non-dia...